Genetic alterations crossing the borders of distinct hematopoetic lineages and solid tumors: Diagnostic challenges in the era of high-throughput sequencing in hemato-oncology

Following the establishment of cytogenetics as well as “traditional” molecular techniques (PCR, fluorescent-based molecular methods such as real-time PCR, and Sanger sequencing) within the last four to five decades, a multitude of genetic alterations have been identified to be typical and crucial for distinct hematologic entities, like t(9;22)(q34;q 11)/BCR-ABL1 in chronic myeloid leukemia (CML) or t(15;17)/PML-RARA in acute promyelocytic leukemia (APL), and became relevant for diagnosis, classification, prognostication and therapeutic planning in hematologic and solid malignancies.

Source: Critical Reviews in Oncology Hematology - March 29, 2018 Category: Cancer & Oncology Authors: Evgenii Shumilov, Johanna Flach, Thomas Pabst, Martin Fiedler, Anne Angelillo-Scherrer, Lorenz Tr ümper, Raphael Joncourt, Alexander Kohlmann, Ulrike Bacher Source Type: research